Evidence map›Paper›PMID 32910913›Full record

ArticleAmerican journal of human genetics2020

Unsupervised Clustering of Missense Variants in HNF1A Using Multidimensional Functional Data Aids Clinical Interpretation.

Sara Althari, Laeya A Najmi, Amanda J Bennett, Ingvild Aukrust, Jana K Rundle, Kevin Colclough, Janne Molnes, Alba Kaci, Sameena Nawaz, Timme van der Lugt and 8 more

Open access · hybridAbstract read
In one paragraph

Article in American journal of human genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Investigating the pathogenicity of the recessivemedRxiv : the preprint server for health sciences · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Molecular characterization and re-interpretation ofFrontiers in endocrinology · 2023
    Article
  18. An intermediate-effect size variant inProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 3 countries.

Sara AlthariOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford OX3 7LE, UK.
Laeya A NajmiCenter for Diabetes Research, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway; Department of Medical Genetics, Haukeland University Hospital, 5021 Bergen, Norway; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305-5101, USA.
Amanda J BennettOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford OX3 7LE, UK.
Ingvild AukrustCenter for Diabetes Research, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway; Department of Medical Genetics, Haukeland University Hospital, 5021 Bergen, Norway.
Jana K RundleOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford OX3 7LE, UK.
Kevin ColcloughInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter EX1 2LU, UK; Exeter Genomics Laboratory, Royal Devon and Exeter NHS Foundation Trust, Exeter EX2 5DW, UK.
Janne MolnesCenter for Diabetes Research, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway; Department of Medical Genetics, Haukeland University Hospital, 5021 Bergen, Norway.
Alba KaciCenter for Diabetes Research, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway; Department of Pediatrics and Adolescents, Haukeland University Hospital, 5021 Bergen, Norway.
Sameena NawazOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford OX3 7LE, UK.
Timme van der LugtHormone Laboratory, Haukeland University Hospital, 5021 Bergen, Norway.
Neelam HassanaliOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford OX3 7LE, UK.
Anubha MahajanOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford OX3 7LE, UK; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
Anders MolvenCenter for Diabetes Research, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway; Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway; Department of Pathology, Haukeland University Hospital, 5021 Bergen, Norway.
Sian EllardInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter EX1 2LU, UK; Exeter Genomics Laboratory, Royal Devon and Exeter NHS Foundation Trust, Exeter EX2 5DW, UK.
Mark I McCarthyOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford OX3 7LE, UK; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK; Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LE, UK.
Lise BjørkhaugDepartment of Safety, Chemistry, and Biomedical Laboratory Sciences, Western Norway University of Applied Sciences, 5020 Bergen, Norway.
Pål Rasmus NjølstadCenter for Diabetes Research, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway; Department of Pediatrics and Adolescents, Haukeland University Hospital, 5021 Bergen, Norway. Electronic address: pal.njolstad@uib.no.
Anna L GloynOxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford OX3 7LE, UK; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK; Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LE, UK; Division of Endocrinology, Department of Pediatrics, Stanford School of Medicine, Stanford University, Stanford, CA 94305-5101, USA.
Haukeland University Hospital · NOUniversity of Oxford · GBGenomics (United Kingdom) · GBOxford Centre for Diabetes, Endocrinology and Metabolism · GBStanford University · USUniversity of Bergen · NOWestern Norway University of Applied Sciences · NO

Funding

Identifying variants causal for Type 2 Diabetes in Major human populationsU01DK085545 · NIDDK · UNIVERSITY OF OXFORD · PI CHAN, JULIANA CN, EBRAHIM, SHAH BRIAN · 2009 to 2013
$2.8M
Integrating genome-scale data to reveal causal mechanisms in type 2 diabetesU01DK105535 · NIDDK · UNIVERSITY OF OXFORD · PI GLOYN, ANNA LOUISE · 2015 to 2019
$1.7M
European Research Council 293574Medical Research Council MR/L020149/1NIDDK NIH HHS U01 DK085545NIDDK NIH HHS U01 DK105535Wellcome Trust 200837/Z/16/Z
6 · The paper itself

Abstract

Exome sequencing in diabetes presents a diagnostic challenge because depending on frequency, functional impact, and genomic and environmental contexts, HNF1A variants can cause maturity-onset diabetes of the young (MODY), increase type 2 diabetes risk, or be benign. A correct diagnosis matters as it informs on treatment, progression, and family risk. We describe a multi-dimensional functional dataset of 73 HNF1A missense variants identified in exomes of 12,940 individuals. Our aim was to develop an analytical framework for stratifying variants along the HNF1A phenotypic continuum to facilitate diagnostic interpretation. HNF1A variant function was determined by four different molecular assays. Structure of the multi-dimensional dataset was explored using principal component analysis, k-means, and hierarchical clustering. Weights for tissue-specific isoform expression and functional domain were integrated. Functionally annotated variant subgroups were used to re-evaluate genetic diagnoses in national MODY diagnostic registries. HNF1A variants demonstrated a range of behaviors across the assays. The structure of the multi-parametric data was shaped primarily by transactivation. Using unsupervised learning methods, we obtained high-resolution functional clusters of the variants that separated known causal MODY variants from benign and type 2 diabetes risk variants and led to reclassification of 4% and 9% of HNF1A variants identified in the UK and Norway MODY diagnostic registries, respectively. Our proof-of-principle analyses facilitated informative stratification of HNF1A variants along the continuum, allowing improved evaluation of clinical significance, management, and precision medicine in diabetes clinics. Transcriptional activity appears a superior readout supporting pursuit of transactivation-centric experimental designs for high-throughput functional screens.

Indexed as

Genetic Predisposition to DiseaseMutation, MissenseRegistriesUnsupervised Machine LearningAdolescentAdultAllelesChildCluster AnalysisDatasets as TopicDiabetes Mellitus, Type 2Exome SequencingFemaleGene ExpressionHepatocyte Nuclear Factor 1-alphaHumansHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanbioinformaticscluster analysisdiabetesgeneticsHNF1Amonogenic diabetesprotein functionrare variantstype 2 diabetes

Identifiers

PMID32910913
PMCPMC7536579
OpenAlexW3083789238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.